問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

National Taiwan University Cancer Center

Division of Hematology & Oncology

更新時間：2023-09-19

李日翔Lee, Jih-Hsiang
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 10 個月

Recruiting Trial

232Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李日翔

National Taiwan University Hospital

Division of Thoracic Medicine

List

7Cases

2024-10-01 - 2032-12-31

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-08-01 - 2028-03-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2022-10-01 - 2029-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2015-11-01 - 2025-08-29

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

楊政達
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2017-05-15 - 2020-04-09

Phase III

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects With Extensive Stage Small Cell Lung Cancer (MERU)

  • Condition/Disease

    Extensive Stage Small Cell Lung Cancer

  • Test Drug

    Rovalpituzumab Tesirine(Rova-T)

Participate Sites
9Sites

Terminated8Sites

洪仁宇
Kaohsiung Municipal Gangshan Hospital

未分科

邱昭華
Taipei Veterans General Hospital

Division of Hematology & Oncology

2017-08-24 - 2020-12-31

Phase III

A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared With Topotecan for Subjects With Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) Who Have First Disease Progression During or Following Front-Line Platinum-Based Chemotherapy (TAHOE)

  • Condition/Disease

    Small Cell Lung Cancer (SCLC)

  • Test Drug

    Rovalpituzumab Tesirine(Rova-T)

Participate Sites
4Sites

Terminated4Sites

2011-12-07 - 2014-06-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB